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Endocrine and Metabolic ResearchReviewAssociations between male reproductive health and exposure to
endocrine-disrupting chemicals
Wiwat Rodprasert1, Katharina M. Main2, Jorma Toppari1,2,3 and
Helena E. Virtanen1Abstract
The incidence of many male reproductive disorders, including
cryptorchidism and testicular cancer has increased. Semen
quality in several countries has declined. Exposure to endo-
crine-disrupting chemicals (EDCs) — both prenatal and
postnatal — has been proposed to have a role in these trends
based on experimental data and animal studies. There is
epidemiological evidence for an association between prenatal
exposure to EDCs and cryptorchidism, hypospadias, and
decreased anogenital distance, as well as an association be-
tween an exposure to EDCs in adulthood and semen quality.
However, some of these findings are inconsistent across
studies. There is less evidence about the role of prenatal
exposure to EDCs for semen quality, and only few studies have
investigated the role of prenatal EDC exposure in testicular
cancer occurrence. This is due to a lack of long-term follow-up
studies linking prenatal exposures with male reproductive
disorders in adulthood. More research is needed investigating
the role of EDC exposure for male reproductive health,
particularly long-term follow-up studies to assess the out-
comes in adulthood.
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Reports on increasing rates of male reproductive health
problems, such as testicular cancer and undescended
testis (cryptorchidism) or declining semen quality, have
been published over last few decades [1e4]. According
to the testicular dysgenesis syndrome hypothesis,
cryptorchidism, hypospadias, testicular germ cell cancer,
and poor semen quality have a shared origin in the fetal
period [5]. Testicular dysgenesis syndrome may present
also as reduced anogenital distance (AGD) in
male individuals and reduced testosterone levels in adult
men [6]. In addition to genetic factors, especially
exposure to environmental and lifestyle factors has been
suggested to influence testicular development and
function [6](see Figure 1). In the following text, we will
review the most recent literature on the association be-
tween exposure to endocrine-disrupting chemicals
(EDCs) and selected topics of male reproductive health.
We focused on original human studies, meta-analyses,
and systematic reviews published betweenOctober 2016
and October 2018. More background information on
EDCs and AGD, cryptorchidism, hypospadias, and
testicular cancer is provided in recent reviews [7,8].Anogenital distance
Mild analgesics and antifungal medication
The length of the AGD is considered a readout of the
prenatal androgen action in males [9]. Three recent
studies have investigated the association between the
anogenital distance and maternal use of medication
during pregnancy [10e12]. AGD was defined as
anoscrotal distance (the distance between the center of
the anus and the posterior base of the scrotum) or as
anopenile distance (the distance between the center of
the anus and the anterior base of the penis).
In a prospective baby cohort from Cambridge, UK, in-
formation on maternal medication during pregnancy was
based on a perinatal questionnaire and sons were
followed up until 24 months of age [10]. AGD mea-
surements (anoscrotal distance) of over four hundred
boys were available. Exposure to paracetamol during
gestational weeks 8e14, but not during other periods,
was associated with a reduced AGD (by 0.3 standard
deviation [SD], 95% confidence interval [CI] 0.1e0.5)
from birth to the age of 24 months [10].urrent Opinion in Endocrine and Metabolic Research 2019, 7:49–61
Figure 1
Testicular dysgenesis syndrome. Adverse maternal lifestyle, exposure to endocrine-disrupting chemicals, genetic defects, and polymorphisms may
affect the development of the fetal testis and disturb the function of the Leydig cells and Sertoli cells and the differentiation of the germ cells. This can
result in a variety of male reproductive system abnormalities — both short-term and long-term manifestations. AGD, anogenital distance; INSL3, insulin-
like peptide 3.
50 Endocrine disruptorsIn two studies based on a Danish motherechild cohort,
557 and 812 duos, respectively, were included. Informa-
tion on medication was collected via two questionnaires
during pregnancy, and AGD (anoscrotal and anopenile
distance) was measured three months after the expected
delivery date [11](12). Maternal use of oral fluconazole
tablets, but not vaginal antifungal medication, was asso-
ciated with a significant decrease in AGD (anoscrotal
distance) (6.4 mm, 95% CI 0.9e11.9) [11]. Prenatal
exposure to mild analgesics (paracetamol and other an-
algesics) was associated with a significant decrease in
AGD (anoscrotal distance) (4.1 mm, 95% CI 1.7e6.4),
and exposure to paracetamol only showed a similar ten-
dency [12]. No association between medications during
pregnancy and the anopenile distance was found [11,12].
The results of the aforementioned human studies are
consistent with some experimental data in rodents,
which found a reduced AGD in male offspring after in
utero exposure to ketoconazole and mild analgesics
[reviewed in Ref. [13]].
Phthalates
Association between prenatal phthalate exposure
(phthalate levels in maternal urine as a proxy) and AGD
in infant boys was evaluated in a systematic review [14].
As phthalates are nonpersistent, exposure levels can vary
considerably between and within individuals over time.Current Opinion in Endocrine and Metabolic Research 2019, 7:49–61Moderate evidence for an inverse association (support-
ing a hazard) between anogenital distance and exposure
to di (2-ethylhexyl) phthalate (DEHP) and dibutyl
phthalate (DBP) was reported [14]. For di-isononyl
phthalate, di-isobutyl phthalate, butyl benzyl phtha-
late, and diethyl phthalate current data were not suffi-
cient to reach a conclusion. A recent prospective cohort
study from Canada that was not included in the sys-
tematic review found no statistically significant associ-
ation between phthalate levels in a maternal first
trimester spot urine sample and anoscrotal distance in
the newborn sons (n = 198) [15]. The anopenile dis-
tance was positively associated with the level of mono-n-
butyl phthalate and the molar sum of phthalates with
low molecular weight [15].
Phenols
In a study from Cyprus, the association between cord
blood levels of bisphenol A (BPA) and AGD (anoscrotal
and anopenile distance) in healthy newborn boys
(n = 72) was studied [16]. AGD (anoscrotal distance)
was significantly shorter in boys whose cord blood BPA
level was above the 90th percentile [16]. A previous
study has suggested an association between shortened
AGD (anopenile distance) in the sons and parental
occupational exposure to BPA during pregnancy (8.1-
mm shorter AGD with maternal exposure) [17].
Maternal urinary levels of BPA and triclosan duringwww.sciencedirect.com
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prospective cohort study from Canada [15]. However,
no statistically significant association between these
chemical levels and AGD (anopenile or anoscrotal dis-
tance) in the newborn sons was found in the study [15].
In a longitudinal Chinese cohort study, association be-
tween BPA levels in maternal urine during pregnancy
and AGD (anoscrotal and anopenile distance) in the
sons at birth at 6 and 12 months of age was studied [18].
Maternal exposure to BPA was associated with a signif-
icantly reduced AGD (2.9 mm shorter anopenile dis-
tance and 4.1 mm shorter anoscrotal distance) in the
sons only at the age of 12 months [18].
Pesticides, polychlorinated biphenyls, and flame
retardants
In a study based on the aforementioned Danish
motherechild cohort, associations between AGD in the
sons at three months (n = 419) and maternal urine
levels of pesticide metabolites (3-phenoxybenzoic acid,
3,5,6-trichloro-2-pyridinol, 2,4-dichlorophenoxyacetic
acid, and dialkyl phosphates) during pregnancy were
studied [19]. No consistent dose-related association
between maternal pesticide metabolite levels and AGD
(anoscrotal or anopenile distance) in the sons was
observed in the study [19].
In a Spanish study based on a motherechild cohort, the
anogenital index (anoscrotal distance divided by weight)
of the sons at 18 months (n = 43) was recorded [20].
Associations between AGI and maternal serum levels of
polybrominated diphenyl ethers (PBDEs) and organo-
chlorine compounds (hexachlorobenzene, dichlor-
odiphenyltrichloroethane (DDT) metabolites, and
polychlorinated biphenyls [PCBs]) during the first
trimester of pregnancy were analyzed. Significant
negative associations between AGI at 18 months and
maternal levels of PBDE-99 and PBDE-153 were re-
ported [20].Cryptorchidism and hypospadias
Pesticides
The association between environmental exposure to
pesticides and cryptorchidism or hypospadias was
examined in a large Spanish populationebased casee
control study (963 and 678 cases with cryptorchidism
and hypospadias, respectively, and 587,142 controls)
[21]. The risk of cryptorchidism and hypospadias was
increased (odds ratio [OR] 9.0, 95% CI 7.9e10.2 and
OR 5.7, 95% CI 4.9e6.7, respectively) in areas of high
pesticide use compared with areas of low use [21]. Some
previous studies have also suggested positive or inverted
U-shaped associations between the level of use of pes-
ticides and the rates of cryptorchidism (e.g. OR for
being a case 2.3, 95% CI 1.3e4.3 in the highest exposurewww.sciencedirect.com Ccategory [22]) and hypospadias in the same area [22e
24].
A caseecontrol study (25 cases and 58 controls) from
France evaluated the association between isolated
hypospadias and meconium levels of pesticides or me-
tabolites (organophosphates, carbamates, phenylurea,
and phenoxyherbicides) [25]. The presence of the
phenylurea herbicide isoproturon and phenoxyherbicide
2-methyl-4-chlorophenoxyacetic acid in meconium was
associated with the risk of hypospadias (OR 5.9, 95% CI
1.0e34.1 with moderate exposure and OR 4.8, 95% CI
1.2e18.8, respectively) [25].
Flame retardants
A Canadian caseecontrol study (137 cases, 158 controls)
examined the association between operated congenital
cryptorchidism and maternal hair levels of PBDEs as a
proxy for fetal exposure [26]. The risk of cryptorchidism
was positively correlated to maternal hair levels of BDE-
99, BDE-100, and BDE-154 (OR 2.5, 95% CI 1.3e5.0,
OR 2.5, 95% CI 1.3e4.6, and OR 1.9, 95% CI 1.1e3.3,
respectively, for every 10-fold increase in BDE levels)
[26]. Another caseecontrol study (152 cases, 64 controls
from Canada) evaluated the association between isola-
ted hypospadias and PBDE levels in maternal hair as a
proxy for fetal exposure [27]. Hair samples were
collected when the child was 3e18 months old.
Maternal hair total PBDE levels were significantly
higher in boys with hypospadias as compared with the
control boys [27]. A previous study reported a positive
association between congenital cryptorchidism and the
levels of PBDEs in maternal breast milk, but not in the
placenta [28]. In another study, maternal serum levels of
polybrominated biphenyls, as a proxy for in utero expo-
sure to polybrominated biphenyls, were not associated
with the risk of cryptorchidism or hypospadias in the
sons [29].Glycol ethers
A matched caseecontrol study nested in two joint
French motherechild cohorts studied the association of
exposure to glycol ethers (GE, levels in maternal urine
as a proxy) with the prevalence of cryptorchidism and
hypospadias [30]. Cases had persistent or operated
cryptorchidism (n = 14) or hypospadias (n = 15)
confirmed by a specialist. Exposure to methoxyacetic
acid, but not to phenoxyacetic acid, was significantly
associated with the risk of hypospadias (OR 4.5 95% CI
1.4e23.7 in the highest tertile of exposure), but not
with the risk of cryptorchidism [30]. This was in line
with previous studies suggesting an association between
parental exposure to solvents and the risk of male gen-
ital malformations (OR for cryptorchidism 2.0, 95% CI
1.0e3.9, OR for hypospadias 2.4, 95% CI 1.2e4.8,urrent Opinion in Endocrine and Metabolic Research 2019, 7:49–61
52 Endocrine disruptorssignificant only in univariate analysis [31], and OR for
male genital malformations 3.6, 95% CI 1.1e11.4 [32]).
Analgesics
A systematic review and meta-analysis included ten
studies that evaluated the association between crypt-
orchidism and the use of analgesia during pregnancy
[33]. The analysis suggested a weak association between
ever use of analgesia during pregnancy and risk of
cryptorchidism (pooled crude OR 1.1, 95% CI 1.0e1.2).
In addition, a weak evidence for a relationship of the risk
with both the duration and timing of exposure was re-
ported. However, meta-analyses of a doseeresponse
relationship and timing of exposure to analgesics could
not be performed because of data limitations [33]. The
prospective baby cohort study from Cambridge, UK, did
not find an association between testicular descent and
exposure to paracetamol during pregnancy [10]. How-
ever, this result may have been influenced by the rela-
tively small number of cryptorchid boys in the cohort
(33 at birth, 62 at any age) [10].
Phthalates and perfluorooctane sulfonate
The systematic review of Radke et al. evaluated also the
association between prenatal phthalate exposure and
cryptorchidism or hypospadias [14]. The evidence for
any association was, however, weak or uncertain for all
six phthalates studied (DEHP, di-isononyl phthalate,
DBP, di-isobutyl phthalate, butyl benzyl phthalate,
diethyl phthalate) [14]. In a caseecontrol study
analyzing perfluorooctane sulfonate levels and levels of
DEHP and DiNP metabolites in amniotic fluid during
gestational weeks 13e16, no association between these
chemical levels and cryptorchidism or hypospadias was
found [34].
EDCs in general
In a French caseecontrol study (57 cases, 162 matched
controls), associations between hypospadias in the
offspring and maternal occupational and household ex-
posures was examined [35]. Information on maternal
occupation and exposures during first trimester was
collected postnatally via a questionnaire. Household use
of hair care products was linked with a risk of hypospadias
(adjusted OR 6.1, 95% CI 1.1e34.9, significant only after
adjustment) [35]. Potential maternal occupational expo-
sure to EDCs (based on a validated job-exposure matrix)
was also associated with an increased risk of hypospadias
(adjusted OR 9.6, 95% CI 1.4e66.1) [35]. Several previ-
ous studies have also suggested that maternal occupa-
tional exposure to EDCs in general is associated with the
risk of hypospadias [36e39], but results concerning
different chemical groups have been variable.
A meta-analysis aimed to evaluate the overall risk of
exposure to EDCs for the development of genital
malformations [40]. Different biological matrices wereCurrent Opinion in Endocrine and Metabolic Research 2019, 7:49–61used in the studies to measure a variety of EDCs.
Overall, the relative risk estimate for cryptorchidism
(OR 1.0, 95% CI 0.7e1.5, 16 risk estimates included)
and the risk estimate for hypospadias (OR 1.1, 95% CI
0.9e1.5, 18 risk estimates included) were not statisti-
cally significant. For hypospadias, the available data also
allowed a meta-analysis for specific chemical groups,
that is, for 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene
and polychlorinated biphenyls (PCBs). However, also
these summary estimates were statistically nonsignifi-
cant (OR 1.4, 95% CI 0.9e2.0 and OR 1.1 95% CI 0.6e
2.0) [40].Semen quality
There is evidence for a declining semen quality among
men in North America, Europe, Australia, and New
Zealand [1,41]. EDCs were proposed to have a role in
this finding [42,43]. Most of the studies that investi-
gated the relationship between EDC exposure and
semen quality are focused on the exposure during
adulthood. There are limited numbers of studies on
prenatal exposure. Table 1 summarizes recent studies on
the association between EDC exposure and the semen
quality assessed by standard procedures of semen
analysis.
Prenatal exposure to EDCs and semen quality
Hart et al. studied the relationship between prenatal
maternal exposure to BPA or phthalates and semen
quality of the sons at the age of 20e22 years in the Raine
pregnancy cohort study. The main findings are summa-
rized below.
Bisphenol A
The BPA levels were measured from the pooled serum
of 284 mothers at 18 and 34 weeks of gestation. After
adjusting for duration of sexual abstinence, varicocele,
and maternal smoking, maternal BPA levels had a small
positive association with sperm concentration and pro-
gressive sperm motility [44].
Phthalates
Maternal prenatal serum mono-ethyl phthal-
ate concentration was negatively associated with semen
volume, and the mono-carboxy-iso-octyl phthalate con-
centration was negatively associated with spermmotility
[45].
To date, there are a small number of longitudinal studies
assessing the association between prenatal exposure to
EDCs and the semen quality [40,46]. The correlation is
still unclear, except for some rare cases of occupational
or environmental accidents where men with perinatal
exposure to dioxin in Seveso, Italy [47], or prenatal
exposure to PCBs and polychlorinated dibenzofurans in
Taiwan (YuCheng accident) [48] have shown a reduced
semen quality after prenatal exposure.www.sciencedirect.com
Table 1
List of articles on the association between exposure to endocrine-disrupting chemicals (EDCs) and semen quality published in October 2016–October 2018.
EDC
Reference (year)
Country
Study design
Population
Exposure
assessment
Samples for exposure
Samples for outcome
Associations
BPA
Adoamnei E (2017) [50] Spain
Cross-sectional
215 university students, aged 18–23
years
Concurrent Urinary BPA
One semen sample
Negative association (sperm
concentration and total sperm count)
Hart RJ (2018) [44] Australia
Prospective pregnancy cohort
136 men, aged 20–22 years
Prenatal Maternal serum BPA at 18 and 34 weeks’
gestation
One semen sample
Weak positive association (sperm
concentration and motility)
Hu W (2017) [51] China
Cross-sectional
357 subfertile male volunteers, aged
18–43 years
Concurrent Urinary BPA
One semen sample
Negative association (total sperm count,
only in obese men)
Radwan M (2018) [52] Poland
Cross-sectional
315 men, aged <45 years, with sperm
concentration  15 million/ml
Concurrent Urinary BPA
One semen sample
Negative association (sperm motility)
PCBs
Hsu PC (2016) [55]
(PCBs and PCDFs)
Taiwan
Cohort
2 study groups:
50 men exposed to PCBs and PCDFs and
34 neighborhood referents, aged 37–50
years
Adulthood PCBs and PCDFs in blood in exposed
men (not reported)
One semen sample
Abnormal sperm morphology (%) was
higher in the exposed men than the
unexposed men.
Mínguez-Alarcón L (2017) [54] Russia
Cohort
Healthy boys at the age of 8–9 years
(n = 516) and 18–19 years (n = 133)
Childhood Serum PCBs
1 or 2 semen sample(s) at 18–19 years of
age
No associations
Paul R (2017) [57] Spain
Cross-sectional
2 groups of men from subfertile couples
seeking infertility diagnosis aged 30–55
years
- low semen quality (had at least 1
abnormal semen variable) (n = 24)
- normal semen quality (all semen
variables were above WHO reference
limits) (n = 26)
Concurrent Serum DL-PCBs
1 semen sample
Total PCB levels in the low semen quality
group were higher than that in the normal
semen quality group.
Among men with normal semen quality
negative associations:
- PCB-118 (semen volume)
- PCB-189 (progressive motility)
positive associations:
- PCB-77, -123, total nonortho PCBs
(sperm with normal morphology)
Among men with low semen quality,
positive associations:
- PCB-118, mono-ortho PCBs,
P
DL-
PCBs (semen volume)
- PCB-77, PCB-81 (sperm with normal
morphology)
(continued on next page)
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Table 1. (continued )
EDC
Reference (year)
Country
Study design
Population
Exposure
assessment
Samples for exposure
Samples for outcome
Associations
Petersen MS (2018) [53] Faroe Island
Cross-sectional
263 men aged 24–26 years
Concurrent PCBs in blood
One semen sample
No associations
PBDEs
Albert O (2018) [59] Canada
Cross-sectional
153 healthy men aged 18–41 years
Concurrent PBDEs in hair samples
One semen sample
No associations
Yu YJ (2018) [60] China
Comparative cross-sectional
Cases: 32 men (20–50 years) residing at
an e-waste dismantling workshop
Controls: 25 men (aged 24–46 years)
Concurrent PBDEs in house dust
PBDEs in seminal fluid
One semen sample
Cases had lower total sperm count,
progressive motility, and total motile
spermatozoa than controls.
Negative associations:
- Seminal BDE-47 (sperm concentration
and total sperm count)
- BDE-100 in dust (sperm progressive
motility and viability)
Phthalates
Nassan FL (2016) [67] USA Concurrent No measurement of DBP level
One semen sample
At baseline, semen quality between the
two groups was not different.
Intervention period:
Arm1: sperm motility decreased during
crossover and crossback.
Arm 2: no change of semen quality
Men with inflammatory bowel disease
taking mesalamine aged 18–55 years
Crossover–crossback prospective
Arm 1: non-DBP–containing mesalamine
at baseline, then crossover for 4 months
to high DBP, followed by crossback for 4
months to non-DBP mesalamine (n = 26)
Arm 2: high-DBP mesalamine at baseline,
followed by 4 months non DBP, then 4
months high-DBP mesalamine (n = 47)
Chen Q (2017) [69] China
Cohort
796 male students who moved to a
different university campuses (median
age: 20 years)
Concurrent Urinary phthalate metabolites
One urine and semen sample before and
after relocation
Negative associations:
- mEP (sperm concentration)
- mEP, MnBP, MCPP, and sum of LMWP
(sperm motility)
- MnOP, MEHP, and sum of HMWP
(sperm with normal morphology)
Positive associations:
- miBP and MEHP (semen volume)
- MnOP (progressive motility)
- MBzP (sperm with normal morphology)
After relocation, levels of all phthalates
metabolites, except MEHP, decreased
along with increased semen volume and
sperm with normal morphology.
Chang WH (2017) [64] Taiwan
Cross-sectional
Male partners of subfertile (n = 253) and
fertile (n = 37) couples (mean age: 33
years)
Concurrent Urinary and seminal phthalate
metabolites
One semen sample
Negative associations:
- Urinary MBzP and MEHP (sperm
concentration and sperm motility)
- Seminal MEHP and mono-2-ethyl-5-
hydroxyl phthalate levels (sperm
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concentration), MEP level (sperm
motility and normal morphology), DEHP
level (sperm motility).
Albert O (2018) [59] Canada
Cross-sectional
153 healthy men aged 18–41 years
Concurrent Urinary phthalate metabolites
One semen sample
No associations
Broe A (2018) [68] Denmark
Case-control
Danish men in the Danish IVF register
(2006–2016)
Median age: 34 years
Cases: men with low semen quality
Controls: men with normal semen quality
In the past 3 months, 57 cases and 72
controls received a prescription for
medication containing phthalates and
1421 cases and 2370 controls for
phthalate-free drugs
Concurrent No measurement phthalates level Men who received phthalate-containing
medications had an increased risk of poor
semen quality as compared with men who
received phthalate-free drugs (OR 1.3,
95% CI 0.9–1.9).
Hart RJ (2018) [45] Australia
Prospective pregnancy cohort
111 men, aged 20–22 years
Prenatal Maternal serum at 18 and 34 weeks’
gestation for phthalate diesters and
metabolites
One semen sample of the son at 20–22
years of age
Negative associations:
- MEP (semen volume)
- MCiOP (sperm motility)
Smarr MM (2018) [63] USA
Cross-sectional
339 male partners of couples
discontinuing contraception to become
pregnant, mean age 31.8 years
Concurrent Seminal plasma phthalate diesters and
monoesters
Two semen samples
Negative associations:
- monoesters metabolite (mEP, mBP,
miBP, mBzP) (semen volume)
Dioxins
Mínguez-Alarcón L (2017) [54] Russia
Cohort
Healthy boys at the age of 8–9 years
(n = 516) and 18–19 years (n = 133)
Childhood Serum TCDD, PCDDs
1 or 2 semen samples at 18–19 years of
age
Negative associations (sperm
concentration, total sperm count, and total
motile sperm count)
Perfluorinated compounds
Petersen MS (2018) [53]
Faroe Island
Cross-sectional
263 men, aged 24–26 years
Concurrent Blood for PFASs levels (PFOA, PFOS,
PFHxS, PFNA, and PFDA)
One semen sample
No associations
Song X (2018) [58] China
Cross-sectional
103 men, aged varied
Concurrent Blood and semen PFAAs Blood: positive associations (PFBA,
PFPeA, and PFBS and progressive
sperm motility)
negative associations (PFOA and PFOS
and progressive sperm motility)
Semen: negative associations (Sum of
PFAAs, PFBA, PFPeA, PFHxA, PFBS,
PFOA, PFHS, PFOS, and progressive
sperm motility)
Insecticides/pesticides
Cremonese C (2017) [72] Brazil
Comparative cross-sectional
99 rural and 36 urban men aged 18–23
years
Concurrent No chemicals measurements
One semen sample
Rural men, 60% were farmers and most
reported use of pesticides > 1 year, had
higher sperm concentration, but lower
percentage of sperm with normal
morphology.
Segal TR (2017) [70] USA
Cross-sectional
Concurrent 1–2 urine samples for DCBA levels
1 semen samples
No associations
(continued on next page)
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Table 1. (continued )
EDC
Reference (year)
Country
Study design
Population
Exposure
assessment
Samples for exposure
Samples for outcome
Associations
90 male partners of couples seeking for
infertility treatment, aged 18–56 years
Parabens
Nishihama Y (2017) [71] Japan
Cross-sectional
42 male partners of couples who came for
infertility consultation (mean age 37
years)
Concurrent Urinary paraben concentrations
One semen sample
No associations
Benzophenone-type ultraviolet
filters
Adoamnei E (2018) [73]
Spain
Cross-sectional
215 university students, aged 18–23
years
Concurrent Urinary benzophenone-type ultraviolet
filters
One semen sample
No associations
Medications
Analgesics
Høyer BB (2017) [74]
3 separate studies in England, Belgium,
Italy, Denmark, Greenland, Poland,
Sweden, and Ukraine
Cross-sectional
1493 men
Questionnaire about over-the-counter
analgesics use during the past 6 months
(paracetamol, NSAIDs, or combination
drugs)
Concurrent One semen sample No association between over-the-counter
analgesics use and semen quality
Statins
Keihani S (2018) [75] USA
Retrospective
Men attended fertility clinic
Cases: 118 men who used statins  3
months (mean age 39 years old)
Controls: 7698 men without any
medication use during the past 3 months
(mean age, 32 years old)
Concurrent One semen sample Statins use alone: no association with any
semen variables.
Statins use in combination with other
nonspermatotoxic medications:
association with lowered semen volume.
Persistent organic pollutants (POPs): DL-PCBs, dioxin-like polychlorinated biphenyl; PBDEs, polybrominated diphenyl ethers; PCBs, polychlorinated biphenyls; PCDDs, polychlorinated dibenzo-p-dioxins;
PCDFs, polychlorinated dibenzofurans; PFAAs, perfluoroalkyl acids; PFASs, perfluorinated alkylate substances; PFBA, Pentafluorobenzoic acid; PFBS, Perfluorobutanesulfonic acid; PFDA,
perfluorodecanoic acid; PFPeA; PFHS, Perfluorohexane sulfonic acid; PFHxA, Perfluorohexanoic acid; PFHxS, perfluorohexanesulfonic acid; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid;
PFOS, perfluorooctane sulfonate; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Non-persistent EDCs: BPA, bisphenol A; BzBP, benzyl butyl phthalate; DBP, di-n-butyl phthalate; DCBA, 3-(diethylcarbamoyl) benzoic acid; phthalates; DEHP, di-(2-ethylhexyl) phthalate; HMWP, high-
molecular-weight phthalates; LMWP, low-molecular-weight phthalates; MCiOP, Mono-carboxy-iso-octyl phthalate; MCPP, mono(3-carboxypropyl) phthalate; mBP, mono-n-butyl phthalate; mBzP, mono-
benzyl phthalate; mEP, mono-ethyl phthalate; MEHP, mono-2-ethylhexyl phthalate; miBP, mono-2-isobutyl phthalate; MnBP, mono-n-butylphthalate; MnOP, mono-n-octyl phthalate; parabens.
NSAIDs, nonsteroidal anti-inflammatory drugs; TEQs, toxic equivalents; OR, odds ratio; CI, confidence interval.
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Male reproductive health and EDCs Rodprasert et al. 57Postnatal exposure to EDCs and semen quality
There are a number of recently published studies, which
investigated the association between postnatal
EDC exposure (mainly in adulthood) and semen quality.
These studies used different adjustment criteria, for
example, age, body mass index, duration of sexual
abstinence, time from ejaculation to start of semen
analysis, smoking and alcohol drinking status and vari-
cocele, for analyzing the correlation. This causes chal-
lenges to make direct comparisons between the studies.
The key findings are described below.
Bisphenol A
Previous studies reported that the role of BPA exposure
during adulthood on semen quality is inconclusive,
because the data showed mixed results [49]. However,
data from recent studies supported the potential link
between BPA exposure and low semen quality.
Urinary BPA concentrations were found to have a sig-
nificant negative association with sperm concentration
and total sperm count in a study in 215 young university
students in Spain [50] and in a subgroup of obese men
(26 of 357 study men) in China [51]. A study in 315
men, aged below 45 years, with normal sperm concen-
tration in Poland found a negative association between
urinary BPA concentrations and sperm motility [52].
Polychlorinated biphenyls and dioxins
A cross-sectional study in 263 young Faroese men found
no associations between serum PCBs and any semen
variables [53]. A Russian cohort study followed boys
from the age of 8e9 years (n = 516) until 18e19 years
(n = 133). The serum samples were collected at the age
of 8e9 years and semen samples at 18e19 years. The
serum levels of 2,3,7,8-tetrachlorodibenzo-p-dioxin,
polychlorinated dibenzo-p-dioxins, furans, and PCBs
were measured. Higher quartiles of 2,3,7,8-
tetrachlorodibenzo-p-dioxin and polychlorinated
dibenzo-p-dioxin toxic equivalents were negatively
associated with sperm concentration, total sperm count,
and total motile sperm count. In contrast, serum PCBs,
furans, and total toxic equivalents did not show any as-
sociations with semen quality [54]. A study in Taiwan
found that men who were exposed to PCBs and poly-
chlorinated dibenzofurans by ingestion of contaminated
rice oil during adulthood in 1978e1979 (YuCheng ac-
cident) had a higher percentage of sperm with abnormal
morphology than unexposed men [55]. In summary,
results of the recent PCB studies were different from
previous studies, which showed a link between postnatal
PCB exposure and lower sperm motility [56].
A study in men from subfertile couples in Spain showed
that men with low semen quality (n = 24) had higher
levels of dioxin-like PCBs than men with normal semen
quality (n = 26). Positive associations between somewww.sciencedirect.com Cdioxin-like PCBs and the percentage of sperm with
normal morphology in both subgroups of men were
found. Associations with other semen variables were also
identified (Table 1) [57].
Perfluorinated compounds
A study in 263 young Faroese men found no associations
between serum perfluorinated alkylate substances and
any semen variables [53]. In contrast, a Chinese study,
which measured the levels of perfluoroalkyl acids
(PFAAs) in blood and semen in 103 men, found negative
associations between seminal PFAAs levels and pro-
gressive sperm motility. However, the analysis of corre-
lation between blood PFAAs levels and semen quality
showed mixed results [58]. To date, studies on
perfluorinated compounds have shown conflicting
results.
Polybrominated diphenyl ethers
A cross-sectional study in 153 healthy young Canadian
men found no association of the levels of BDE-47, BDE-
100, and the sum of BDEs with sperm concentration or
motility [59]. A study of 32 Chinese men, living close to
an e-waste dismantling area, measured PBDE levels in
house dust and semen samples. BDE-47 levels in semen
samples were significantly negatively correlated with
sperm concentration and total sperm count, whereas
BDE-100 levels in dust had a significant negative cor-
relation with the percentage of progressive sperm
motility and sperm viability [60]. To date, studies
investigating the role of PBDE exposure on semen
quality have shown mixed results [61,62].
Phthalates
Several studies on the association between postnatal
phthalate exposure and semen quality have recently
been published. Of three cross-sectional studies, two
demonstrated a negative association between urinary or
seminal phthalate levels and semen quality [63,64],
whereas one did not [59]. These findings suggest a link
between postnatal phthalate exposure and lower semen
quality, which are in line with results from the latest
systematic reviews and meta-analysis [14,65,66].
A crossoverecrossback study in US men diagnosed with
inflammatory bowel disease and treated with mesal-
amine compared semen quality of the two intervention
groups d men who were taking non-DBPecontaining
mesalamine (with crossover to high-DBPecontaining
mesalamine and crossback to non-DBP mesalamaine)
and men who were taking high-DBP mesalamine (with
crossover to non-DBP mesalamine and crossback to
high-DBP mesalamaine). At baseline, semen quality of
the men in the two groups was similar. However, the
sperm motility decreased during crossover and
continued to decrease even after crossback in the first
group. The cumulative carryover effects duringurrent Opinion in Endocrine and Metabolic Research 2019, 7:49–61
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7.6% lower total sperm motility (95% CI -13.1 to 2.2),
4.2% lower percentage of progressive sperm motility
(95% CI -8.1 to 0.4), and 26.0% lower motile sperm
count (95% CI 46.2 to 1.7). In contrast, semen quality
did not change in the second group [67]. A caseecontrol
study in Danish men from the in vitro fertilization reg-
ister reported an increased risk of low semen quality in
men who used phthalate-containing medications as
compared with men who used phthalate-free medica-
tions (adjusted OR 1.3, 95% CI 0.9e1.9) [68]. A cohort
study in 796 male students in China observed associa-
tions between some urinary phthalate metabolites and
semen quality [69] (Table 1).
Other EDCs
A study of 90 male partners of couples seeking infertility
treatment in the USA showed no association between
the level of urinary 3-(diethylcarbamoyl) benzoic acid,
which is a metabolite of the insecticide N,N-diethyl-m-
toluamide, and semen quality [70]. One study in 42
Japanese men did not find any association between
urinary parabens and semen quality [71]. A Brazilian
study showed that the men living in a rural area had
higher sperm concentration but lower percentage of
sperm with normal morphology and progressive sperm
motility than men living in an urban area [72] (Table 1).
Urinary levels of benzophenone-type ultraviolet light
filters were not associated with semen quality in a study
in 215 university students in Spain [73].
Medications
A combined data analysis of three occupational and
environmental cohort studies of 1493 men in eight Eu-
ropean countries showed no association between the use
of over-the-counter analgesics (paracetamol, nonste-
roidal anti-inflammatory drugs, or drugs containing both
analgesics and other medications) and semen quality
[74]. One study compared semen quality of the men
attending a fertility clinic who used or did not use
statins and found that semen quality of the men in two
groups was not different. However, using statins
together with other medications is associated with a 0.3-
ml decrease of semen volume (95% CI 0.02e0.6,
p = 0.04) [75].Testicular cancer
The prevalence of testicular germ cell tumors (TGCT)
has been increasing in several countries [2,76]. Experi-
mental and epidemiological studies support the hy-
pothesis that TGCT has an origin in fetal life [6].
However, there is no longitudinal follow-up study
examining the relationship between prenatal EDCs
exposure (by measuring the EDCs from the maternal
samples during pregnancy, placenta, or cord blood) and
testicular cancer in adulthood. This is most likely due toCurrent Opinion in Endocrine and Metabolic Research 2019, 7:49–61the long time lag between the two events, and the
disease is not common.
The meta-analysis in 2016 included eight case-referent
studies that investigated the prenatal exposure to EDCs
and the risk of TGCT [40]. One study used maternal
serum collected from the early postpartum period. Two
studies measured persistent organic pollutants levels
from the mothers’ blood at the time of the sons’ diag-
nosis of TGCT. The rest of the studies used serum
persistent organic pollutants levels measured from the
testicular cancer cases before or at the time of diagnosis
as a proxy for prenatal exposure. The result showed that
EDC exposure marginally increased the risk of TGCT
(OR 1.2, 95% CI 0.8e1.9) [40].
Findings from the NORD-TEST study, which is a
registry-based TGCT caseecontrol study in Denmark,
Finland, Sweden, and Norway, have recently been
published. The first and second substudy included 8112
TGCTcases, aged 14e49 years, from 1978 to 2012, and
26,264 controls in Finland, Norway, and Sweden. The
data on parental occupations before delivery were
extracted from the censuses. The first substudy found
no association between prenatal parental occupational
exposure to organic solvents and TGCT in the sons.
However, a subgroup analysis of mothers with available
prenatal occupational data showed that maternal expo-
sure to aromatic hydrocarbon solvents increased the risk
of TGCT (OR 1.5, 95% CI 1.1e2.2) [77]. The second
substudy found either no association between the
parental exposure to heavy metals/welding fumes and
the risk of TGCT in the sons except among fathers who
were exposed to high chromium levels (compared with
no chromium OR 1.4, 95% CI 1.1e1.8) [78]. The third
substudy included 3421 cases and 14,024 controls from
Denmark. Similarly, no significant association between
parental exposure to solvents or heavy metals and the
risk of TGCT in sons was found (OR for maternal
exposure to both solvents and heavy metals 1.1, 95% CI
0.9e1.2, and OR for paternal exposure 1.0, 95% CI 0.9e
1.2) [79]. However, the risk of TGCTwas increased in
the sons with paternal exposure to heavy metals other
than lead (most of them were exposed to both chro-
mium VI and toluene) (OR 1.5, 95% CI 1.0e2.2) [79].
Personal care products contain chemicals, some of which
have endocrine-disrupting effects. One study evaluated
the association between maternal use of personal care
products during pregnancy and breastfeeding and the
risk of TGCT in the sons. The study included 527
mothers of TGCT cases and 562 mothers of controls.
The result showed that the maternal use of facial lotion
more often than once per week was associated with an
increased risk of TGCT in the sons (OR 1.4, 95% CI
1.1e1.9) [80].www.sciencedirect.com
Male reproductive health and EDCs Rodprasert et al. 59The relationship between environmental exposure in
adulthood and TGCT is not clearly demonstrated. This
is consistent with the hypothesis that TGCT has a fetal
origin [81].Conclusions
An increasing number of studies suggest that there may
be associations between the exposure to EDCs and
cryptorchidism, hypospadias, reduced anogenital dis-
tance, and semen quality in man. However, there are
also many studies showing no effects which leads to
inconsistencies. Some of these may be caused by dif-
ferences in study designs, sample sizes, methods of
exposure assessment, and the timing of exposure.
Furthermore, humans are exposed to a large cocktail of
chemicals which may have additive effects and are still
challenging to evaluate. Data on the relationship be-
tween exposure to EDCs and development of TGCT is
still limited because of the long interval between fetal
origin and adult cancer. More research is needed in
particular of the association between prenatal and early
life exposures to EDCs and semen quality in young
adulthood.Conflict of interest statement
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